Sareum (LON:SAR) Announces Quarterly Earnings Results

Sareum (LON:SAR) issued its quarterly earnings data on Tuesday. The company reported GBX (0.90) (($0.01)) EPS for the quarter, Digital Look Earnings reports.

Sareum Stock Performance

Shares of SAR traded up GBX 0.99 ($0.01) during mid-day trading on Thursday, hitting GBX 12.99 ($0.17). 961,760 shares of the company’s stock were exchanged, compared to its average volume of 420,713. Sareum has a fifty-two week low of GBX 10 ($0.13) and a fifty-two week high of GBX 52.50 ($0.68). The company has a market cap of £16.23 million, a price-to-earnings ratio of -3.08 and a beta of -1.08. The stock’s 50-day moving average is GBX 17.82 and its 200-day moving average is GBX 23.19.

Insiders Place Their Bets

In other Sareum news, insider Stephen Parker purchased 84,033 shares of the business’s stock in a transaction on Wednesday, March 26th. The shares were bought at an average cost of GBX 12 ($0.15) per share, for a total transaction of £10,083.96 ($12,983.08). Insiders own 5.02% of the company’s stock.

Sareum Company Profile

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.